What is imbruvica?
imbruvica (Ibrutinib) is a cure for cancer that prevents the growth and spread of cancimbruvicaer cells in the body. Imbruvica dosage is used to treat certain types of non-Hodgkin's lymphoma including mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia and chronic lymphocytic leukemia (CHLL) / lymphocytic lymphoma (LLL) in people with or without 17 p. removal.
Imbravitsa is sometimes given when other medications are not effective.
Imbruvica has been approved for the treatment of mantle cell lymphoma by the US Food and Drug Administration (FDA) on an "accelerated basis. In clinical studies, the tumor responded to this drug. However, it has not been shown that ibrutinib can improve symptoms or prolong survival time in people Imbruvica Overdose with this type of lymphoma.
Follow all instructions on the label and packaging. Let each of your health workers know about all your medical conditions, allergies, and any medications you use.
Slide Show 2016 New drug approvals: The year that was the instruction
Before you take this medicine.
You should not use Imbruvica if you are allergic to ibrutinib.
To make sure that Imbruvica is safe for you, please inform your doctor if you have one:
- Kidney disease;
- liver disease;
- Active infection;
- Bleeding or clotting disorder, such as hemophilia;
- Heart rhythm disorder;
- Risk factors for heart disease (such as diabetes, smoking, being overweight, high blood pressure or high cholesterol);
- If you take a blood thinner (warfarin, cumadin, gentlemen);
- If you recently had surgery.
Using Imbruvica can increase the risk of developing other cancers such as skin cancer. Ask your doctor about your specific risk.
Do not use Imbruvica if you are pregnant. It may harm your https://pillintrip.com/medicine/imbruvica unborn child. You may have to take a negative pregnancy test before you start this treatment.
Use effective birth control to prevent pregnancy while you use this medicine, whether you are male or female. Using Ibrutinib by one of your parents can cause birth defects. Continue to use birth control for at least 1 month after the last dose of Ibrutinib.
It is not known whether ibrutinib www.ncbi.nlm.nih.gov/pubmed?Term=Imbruvica passes into breast milk or if it can harm the baby. You should not breast-feed when using this medicine.